Dux Ducis Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 19-06-2024
- Paid Up Capital ₹ 0.10 M
as on 19-06-2024
- Company Age 10 Year, 9 Months
- Last Filing with ROC 31 Mar 2019
- Open Charges ₹ 1.88 M
as on 19-06-2024
- Revenue -55.80%
(FY 2019)
- Profit -851.09%
(FY 2019)
- Ebitda -657.65%
(FY 2019)
- Net Worth -77.17%
(FY 2019)
- Total Assets -1.30%
(FY 2019)
About Dux Ducis Pharmaceuticals
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2019. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.88 M.
Yogesh Kanchalwar, Vaibhav Pande, Vivekanand Manwatkar, and Three other members serve as directors at the Company.
- CIN/LLPIN
U51101MH2014PTC254173
- Company No.
254173
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
12 Mar 2014
- Date of AGM
30 Sep 2019
- Date of Balance Sheet
31 Mar 2019
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Thane, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Dux Ducis Pharmaceuticals?
Board Members(6)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Yogesh Kanchalwar  | Additional Director | 15-Dec-2018 | Current |
| Vaibhav Pande | Additional Director | 15-Dec-2018 | Current |
| Vivekanand Manwatkar | Additional Director | 18-Sep-2017 | Current |
| Prashant Pakhidde | Additional Director | 18-Sep-2017 | Current |
| Anuradha Giri | Director | 10-Dec-2014 | Current |
| Vaibhav Giri | Director | 12-Mar-2014 | Current |
Financial Performance of Dux Ducis Pharmaceuticals.
Dux Ducis Pharmaceuticals Private Limited, for the financial year ended 2019, experienced significant reduction in revenue, with a 55.8% decrease. The company also saw a substantial fall in profitability, with a 851.09% decrease in profit. The company's net worth observed a substantial decline by a decrease of 77.17%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Dux Ducis Pharmaceuticals?
In 2019, Dux Ducis Pharmaceuticals had a promoter holding of 50.00% and a public holding of 50.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Punjab National Bank Creation Date: 31 Jul 2015 | ₹1.88 M | Open |
How Many Employees Work at Dux Ducis Pharmaceuticals?
Unlock and access historical data on people associated with Dux Ducis Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Dux Ducis Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dux Ducis Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
